​

Psychosis & schizophrenia spectrum is a topic in the health domain with significant developments in policy, regulation, and public health impact.

Key developments include fda clears motivista digital therapeutic for negative symptoms of schizophrenia, cannabis-related psychosis hospitalizations rise sharply in victoria, monash university study finds, fda flags four deaths in newron's schizophrenia drug studies, among other significant events and policy changes.

Source: Geo Health Space